NOVEL THERAPEUTIC CANDIDATE IDENTIFIED THROUGH PHARMACOPEIA COLLABORATION ENTERS PRECLINICAL DEVELOPMENT

Pharmacopeia, an innovator in the discovery and development of novel small molecule therapeutics, today announced that a compound identified through the Company's ongoing collaboration with Schering-Plough, has been selected by Schering-Plough for preclinical development. The compound is being evaluated as a potential treatment for metabolic diseases.
PR Newswire